Enhanced anti-tumor effects by combination of tucatinib and radiation in HER2-overexpressing human cancer cell lines
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Enhanced anti-tumor effects by combination of tucatinib and radiation in HER2-overexpressing human cancer cell lines ; volume:24 ; number:1 ; day:6 ; month:8 ; year:2024 ; pages:1-15 ; date:12.2024
Cancer cell international ; 24, Heft 1 (6.8.2024), 1-15, 12.2024
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-024-03458-3
- URN
-
urn:nbn:de:101:1-2410262113080.141342882553
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Amrell, Lukas
- Bär, Eric
- Glasow, Annegret
- Kortmann, Rolf-Dieter
- Seidel, Clemens
- Patties, Ina
- SpringerLink (Online service)
Ähnliche Objekte (12)
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
Gab2 Ablation Reverses the Stemness of HER2-Overexpressing Breast Cancer Cells
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
Visualisation of HER2 homodimers in single cells from HER2 overexpressing primary formalin fixed paraffin embedded tumour tissue
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines
Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
Gab2 Ablation Reverses the Stemness of HER2-Overexpressing Breast Cancer Cells
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
Visualisation of HER2 homodimers in single cells from HER2 overexpressing primary formalin fixed paraffin embedded tumour tissue
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines
Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
Gab2 Ablation Reverses the Stemness of HER2-Overexpressing Breast Cancer Cells
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
Visualisation of HER2 homodimers in single cells from HER2 overexpressing primary formalin fixed paraffin embedded tumour tissue
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines